Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [699]

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides...

Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides...

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz

Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )

Early treatment discontinuation and early oxaliplatin discontinuation for stage...

Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

More from ecancer